- Medopad wins 2018 Pfizer Healthcare Hub competition
- As a result, Medopad will have access to Pfizer’s UK and global network and ressources over the course of the next year
- Medopad aims to use this opportunity to further accelerate growth in UK and overseas markets
Pfizer has today announced that Medopad, the UK-based healthtech company, has won its Healthcare Hub Competition.
The Pfizer Healthcare Hub: London was launched in 2017 to help companies innovating in the healthtech space to realise their potential.
It is designed to help late-stage start-ups to grow and reach more patients and providers faster, by giving them access to Pfizer’s UK and global network and resources.
We are looking forward to collaborating on some exciting projects in the next 12 months to help bring the potential of their technology to more patients in the UK
Alex Gilbert of Medopad said: "The Pfizer healthcare hub will be an excellent opportunity for us to partner with another organisation as motivated to transform patient care as Medopad is.
“Our vision to help people live longer is a big one and we know we will need partners to help us achieve this mission.
“We aim to leverage Pfizer's experience and commitment to the UK healthcare system as well as our technological prowess to further develop the role of digital in the UK healthcare ecosystem.
“We are especially excited to explore the fields of oncology, rare diseases, and neurodegenerative diseases under the guidance of a world-class therapy leader."
Dr Hamish Graham, London manager at the Pfizer Healthcare Hub, added: “The broad array of innovative technology presented to us by the different start-ups at the pitch day was a real privilege to see.
“The judges were impressed by the ambition and focus of Medopad on transforming patients’ lives through innovative solutions to real health problems.
“We are looking forward to collaborating on some exciting projects in the next 12 months to help bring the potential of their technology to more patients in the UK.”
Our vision to help people live longer is a big one and we know we will need partners to help us achieve this mission
Medopad’s mission is to offer unique and personalised care to patients with complex and chronic diseases by transforming the way they connect to their clinicians and healthcare providers remotely and in real time; the ultimate aim being to prevent life-threatening outcomes through predictive analytics.
The company has seen a 400% growth in the value of signed projects year-on-year since 2015, including deals with The Royal Free, Guys, St Thomas’s, GSK, Johnson & Johnson and Boston Scientific.
